로슈는 살인을 그만두고 푸제온을 공급하라!
Roche – Stop Killing and Give Us Fuzeon!
푸제온은 이전 HIV 약제에 내성이 생긴 환자들의 치료에 필수적인 의약품으로서 한국 식약청은 2004년 5월 푸제온을 승인하였다. 그러나 스위스 다국적 제약회사 로슈는 정부와의 약가 협상 실패를 이유로 푸제온 공급을 거부하였다.
로슈는 한국에서 푸제온 약가를 연간 22,000달러를 요구하고 있다. 이 가격은 이미 한국에서 시판되고 있는 HIV 치료제 중 가장 비싼 약제의 두 배에 달하는 가격이다. 에이즈 치료는 병용 요법을 해야 한다는 점을 고려해 보면 환자는 1인당 연간 30,000 달러에서 40,000 달러에 달하는 비용을 지불해야 한다.
로슈는 한국을 포함한 일부 국가에 고가의 약값을 요구함으로써 푸제온 공급을 거부하고 있다. 이는 즉 에이즈 환자들의 푸제온 접근권을 거부하고 있는 것이다.
에이즈 환자들의 의약품 접근권은 대부분의 국가에서 심각한 문제이며 또한 지난 몇 년동안 기존 치료제에 내성이 생긴 환자들이 급격히 증가하고 있는 추세이다. 에이즈 환자들에게 의약품 접근권은 생명을 결정할 수 있는 중요한 문제이다.
로슈가 푸제온의 가격과 공급에 대해서 취하고 있는 전략은 한국을 포함한 전 세계 에이즈 환자들의 생명을 위협하는 것이고 이것은 인간에 대한 범죄이다.
우리는 에이즈 환자가 있는 곳이라면 전 세계 어디라도 환자들이 접근가능한 가격에 푸제온을 공급할 것을 로슈에 강력히 요구하는 바이다.
2008년 10월 7일
단체연명_한국(25)
한국HIV/AIDS감염인연대 KANOS
HIV/AIDS인권연대 나누리+
공공의약센터
동성애자인권연대
한국남성동성애자인권단체 친구사이
인권운동사랑방
건강세상네트워크
건강권실현을위한보건의료단체연합
청년한의사회
인도주의실천의사협의회
건강사회를위한 치과의사협의회
노동건강연대
건강사회를 위한 약사회
사회진보연대
정보공유연대 IPLeft
진보네트워크센터
한국백혈병환우회
진보신당연대회의
HIV감염인 그룹 LOVE4ONE
높이 날아라 HIV/AIDS감염인 공동체 NNHAP
민주노동당
민주노동당 성소수자위원회
건강연대
한국HIV/AIDS감염인협회KAPF
인권단체연석회의
단체연명 – Foreign (28)
Action pour l’humanisation des hopitaux(hospitals humanisation action, Cameroon)
Positive Malaysian Treatment Access & Advocacy Group (Kuala Lumpur, Malaysia)
Act up-Paris (France)
Asia Pacific Network of People Living with HIV/AIDS (APN+)
Public Personalities Against Aids Trust (Harare, Zimbabwe)
Southern Africa Treatment Access Movement (Johannesburg, RSA)
Medsin UK (UK)
Knowledge Ecology International
Initiative for Health Equity & Society
Diverse Women for Diversity
International Peoples Health Council (South Asia)
AIDS Cell, Ibn Sina Academy of Medieval Medicine & Sciences (India)
Federation of Medical and Sales Representatives’ Association of India (India)
People’s Health Movement USA (USA)
Council for Health and Development, Inc (Philippines)
Action against Aids Germany (Germany)
People Like IUs Kolkata (India)
Southern Africa Treatment Access Movement (South Africa)
American Medical Student Association (USA & international)
Treatment Advocacy & Literacy Campaign (Zambia)
Student Global AIDS Campaign (USA)
FACE AIDS of UNC Charlotte (USA)
Phoenix PLUS (Russia)
Umunthu Foundation (Malawi)
Global Access Project(New Your, USA)
ACT UP Philadelphia (Philadelphia, U.S.A)
European AIDS Treatment Group (EATG / Brussels, Belgium)
AIDS Access Foundation(Thai)
Personnel – 한국 (66)
Kwon Minjung (Ewha Woman’s university, School of medicine, S.Korea)
Kim Kiyoung (School of Medicine, Ajou University, S.Korea)
Kim Suji (School of Medicine, Ajou University, S.Korea)
Noh YeounKyeong (School of Medicine, Ajou University, S.Korea)
Kim Junhyung (Sungkyunkwan University School of Medicine, S.Korea)
Park Youngsu (Beautiful Life, Global Health Forum of Seoul National University, S.Korea)
Park Kwangsun (Daegu dentention Center, S.Korea)
Park Kwang Seo(LOVE4ONE, S.Korea)
Noh Yeon-kyeong, Eom Yujin, Hong Seok Joo, Yoon Ji Sang
– (medical students of Ajou University, S.Korea)
Kim Keunyoung(hospital of Inha University, S.Korea)
Kim ji young, Cha myung hee, Lee mi sook (Korean Alliance to Defeat AIDS branch DaeguGyeungbuk. S.Korea)
Mia Son, Kim Wonsik, Lee Jungyun, Garam Oh, Byoungseok Kim, Ki-Ho Park, Kim Jho Gwangsoo, Jun Jaewoo, Jung-won Yoon, Jiwon Yoon, Chunsaeng Lee, Ha-yong Yoon, Suk-wha Yang, Kim Keunyoung, Eom ju-young, Song Hee Han, Bark Kwang-Hun, Sowon Jung, Eun Young Bae, Kang kyeong-yeon, Kim Keunyoung, Jong Geol Lee, Jang Min-hee, Oh Jungkeun, Kim sang sik, Kim Hae-In, Chaetoon Hahn, Hyejin Hwang, Oh Jung-won, Kim dong gil, Jeong Chan Ho, Yong-Joon, Choe, Jong-myeong Kim, Kyu-Yeon Kim, Soung-ai Choi, Deokhee Yi, QJ Choi, Seo bokyeong, Rhee Pyengdo, Kim hyune ju, Leem Y.S. Lee Jae Yong, Seok Kyun Woo, yonmi Kwon, Jingyeong Yoo, Ahn Eun Kyoung, MInWoo Oh North, Jin-OK Byeon, Miran Kwon, Kim Tai Won, Yun Young, Lee hyunok, Yi Sang ho
Personal – Foreign (27)
David Legge (People’s Health Movement, Australia)
Edlira Xhafa (Switzerland)
Mary McMahon (GNSH, Yardley, PA, USA)
Christine Chappuis (Arzier, Switzerland)
Sabina Fejzullaj (Tirana, Albania)
Reinhard Huss (Medical Doctor, Leeds, UK)
K Balasubramaniam (Health Action International Asia-Pacific, Colombo)
Jorge A. Restrepo (IBFAN-GIFA, Switzerland)
Claudio Schuftan (PHM, Vietnam)
Susan Heywood (Australia)
M.K.P. Chandralal (People’s Movement for the Rights of Patients, Sri Lanka)
Christine Perera (Patients for Patients Safety Alliance, Sri Lanka)
GP Baldew (Netherlands)
Nathan Bahr (USA)
Siobhan McCarty (Georgetown Medical AIDS Advocacy Network, USA)
Jorge A Uzcátegui Pérez (Venezuela)
Tarak Banerjee (India)
Brinda Adige (Global Concerns India, India)
Gabrielle Kelly (South Africa)
Tafadzwa Roberta Muropa (Zimbabwe)
Antoinette Nguyen (Emory University School of Medicine, USA)
Firinga Johnson Victorius (France)
Alicia Steele (Alumni of Grand Valley State University, USA)
Chris Curry (USA)
Adedotun Odegbile (Saint James School of Medicine, Netherlands Antilles)
Gopal Dabade (All India Drug Action Network, Drgu Action Forum, India)
Sam sitrin (ACT UP Philadelphia, USA)
<영문>
Roche – Stop Killing and Give Us Fuzeon!
Fuzeon is an important part of combination treatment for people who have viruses that have become resistant to other available anti-HIV drugs. It was approved by the Korea Food & Drug Administration(KFDA) in May, 2004. However, the Swiss drug giant Roche has refused to supply the drug because of the failure of price negotiation with the government.
Roche has claimed $22,000 for the price of Fuzeon in South Korea. The yearly cost of $22,000 is double that of the most expensive HIV treatments existing in the market. And if considering that the drug must be taken in combination with other medicines, the total cost of treatment could reach between $30,000 and $40,000 per patient per year.
Roche is denying the access of people living with HIV/AIDS to the Fuzeon by charging unreasonably high price and even refusing to sell the drug in some countries including South Korea.
Access to treatment for infection with the human immunodeficiency virus (HIV) and AIDS has been problems in most countries and the spread of drug-resistant HIV has accelerated rapidly over the last several years. It is very critical for HIV patients to get access to proper medicines.
Roche’s strategies on pricing and supply for Fuzeon has been threatening the lives of HIV patients over the world as well as in South Korea. It is a crime against humanity. We urge Roche to stop abusing their power and supply Fuzeon at affordable price for every country where there are HIV/AIDS patients.
2008. 10. 7
2008-10-06
